Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Protectivity of Covid-19 Vaccines and Its Relationship with Immune Response and Vaccination Strategy: a One-Year Cohort Study

Ferdi Tanir
,
Burak Mete
ORCID logo ,
Hakan Demirhindi
* ORCID logo ,
Ertan Kara
ORCID logo ,
Ersin Nazlıcan
,
Gülçin Dağlıoglu
,
Filiz Kibar
ORCID logo ,
Salih Cetiner
,
Ceren Kanat
Version 1 : Received: 7 June 2022 / Approved: 8 June 2022 / Online: 8 June 2022 (05:39:30 CEST)

A peer-reviewed article of this Preprint also exists.

Tanir, F.; Mete, B.; Demirhindi, H.; Kara, E.; Nazlican, E.; Dağlıoğlu, G.; Kibar, F.; Çetiner, S.; Kanat, C. Protectivity of COVID-19 Vaccines and Its Relationship with Humoral Immune Response and Vaccination Strategy: A One-Year Cohort Study. Vaccines 2022, 10, 1177. Tanir, F.; Mete, B.; Demirhindi, H.; Kara, E.; Nazlican, E.; Dağlıoğlu, G.; Kibar, F.; Çetiner, S.; Kanat, C. Protectivity of COVID-19 Vaccines and Its Relationship with Humoral Immune Response and Vaccination Strategy: A One-Year Cohort Study. Vaccines 2022, 10, 1177.

Abstract

This prospective cohort study aimed to evaluate the efficacy of COVID-19 vaccine schemes, ho-mologous versus heterologous vaccine strategies, and vaccine-induced anti-S-RBD-IgG antibody response in preventing COVID-19 among 942 healthcare workers one year after vaccination with the inactivated and/or mRNA vaccines. All participants received the first two primary doses of vaccines, 13.6% of them lacked the dose-3, 50.5% the dose-4, and 90.3% the dose-5. Antibody lev-els increased with the increase in number of vaccine doses and also in heterologous vaccine regi-mens. In both inactive and mRNA vaccines, infection rates were significantly higher in 2-dose-receivers, but lower in 4- or 5-dose receivers and increasing the total number of vaccine doses resulted in more protection against infection: the 3-dose regimen yielded 4.71 times more protection, the 4-dose 11.76 times and 5-dose 38.46 times more protection from COVID-19 infec-tion, compared to any 2-dose vaccination regimens. Antibody levels at the end of the first year of 4- or 5-dose-receivers were significantly higher than 2- or 3-dose-receivers. To conclude; increased number of total vaccine doses and anti-S-RBD antibody levels increased the protection from COVID-19 infection. Therefore, four or more doses are recommended in one year, for effective protection, especially in risk groups.

Keywords

SARS-CoV2; inactivated vaccine; mRNA vaccine; COVID-19; homologous vaccination; heterolo-gous vaccination; protectivity

Subject

Medicine and Pharmacology, Pulmonary and Respiratory Medicine

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download PDF

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0
Get PDF Cite Share 0
Bookmark BibSonomy Mendeley Reddit Delicious
×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.